Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

  • Migliaccio-Walle K
  • Getsios D
  • Caro J
 et al. 
  • 2

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

The aim of this study was to evaluate the economic impact of galantamine 16 and 24 mg/d relative to no pharmacologic treatment in the management of mild to moderate Alzheimer's disease (AD) in the United States based on the concept of need for full-time care (FTC). Calculations were made using the Assessment of Health Economics in Alzheimer's Disease model, which applies predictive equations to estimate the need for FTC and the associated costs. The predictive equations were developed from longitudinal data on patients with AD. Inputs to the equations were derived by analyzing the data from 2 randomized, placebo-controlled, galantamine clinical trials. Resource use was estimated from US clinical trial data, and costs were estimated from several US databases. Analyses were carried out over 10 years, and costs and benefits were discounted at 3%. In the base case, 3.9 to 4.6 patients need to start treatment with galantamine to avoid 1 year of FTC, depending on dose. Treated patients spent 7% to 8% more time pre-FTC and 12% to 14% less time requiring FTC, resulting in savings of $2408 to $3601. These results suggest that use of galantamine in patients with AD in the United States could reduce the use of costly resources such as formal home care and nursing homes. (PsycINFO Database Record (c) 2012 APA, all rights reserved)

Author-supplied keywords

  • *Alzheimer's Disease
  • *Drug Therapy
  • *Galanthamine
  • Cholinesterase Inhibitors
  • Economics
  • Health Care Costs

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Kristen Migliaccio-Walle

  • Denis Getsios

  • J Jaime Caro

  • Khajak J Ishak

  • Judith A O'Brien

  • George Papadopoulos

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free